All questions are shown as received by the Trust.
Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?
Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?
Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
a. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
b. R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
c. Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
d. Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
e. R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
f. R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
g. Axicabtagene ciloleucel (Yescarta)
h. Tisagenlecleucel
i. Epcoritamab
j. Loncastuximab tesirine
k. Glofitamab
l. Any other SACT
m. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):
a. Axicabtagene ciloleucel (Yescarta)
b. Tisagenlecleucel
c. Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
d. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
e. Any other treatments
Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:
a. CAR-T Therapy (E.g. Axicabtagene ciloleucel)
b. Stem cell transplant or bone marrow transplant (autologous or allogeneic)
c. Any other treatment
Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?
